High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia
Open Access
- 1 March 2008
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 111 (5), 2573-2580
- https://doi.org/10.1182/blood-2007-07-102525
Abstract
High-dose methotrexate (MTX) has been extensively used for treatment of acute lymphoblastic leukemia (ALL). To determine the optimal dose of MTX in childhood relapsed ALL, the ALL Relapse Berlin-Frankfurt-Münster (ALL-REZ BFM) Study Group performed this prospective randomized study. A total of 269 children with a first early/late isolated (n = 156) or combined (n = 68) bone marrow or any isolated extramedullary relapse (n = 45) of precursor B-cell (PBC) ALL (excluding very early marrow relapse within 18 months after initial diagnosis) were registered at the ALL-REZ BFM90 trial and randomized to receive methotrexate infusions at either 1 g/m2 over 36 hours (intermediate dose, ID) or 5 g/m2 over 24 hours (high dose, HD) during 6 (or 4) intensive polychemotherapy courses. Intensive induction/consolidation therapy was followed by cranial irradiation, and by conventional-dose maintenance therapy. Fifty-five children received stem-cell transplants. At a median follow-up of 14.1 years, the 10-year event-free survival probability was .36 (± .04) for the ID group (n = 141), and .38 (± .04) for the HD group (n = 128, P = .919). The 2 groups did not differ in terms of prognostic factors and other therapeutic parameters. In conclusion, methotrexate infusions at 5 g/m2 per 24 hours, compared with 1 g/m2 per 36 hours, are not associated with increased disease control in relapsed childhood PBC acute lymphoblastic leukemia.Keywords
This publication has 52 references indexed in Scilit:
- High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemiaLeukemia, 2006
- Comparison of Long-Term Neurocognitive Outcomes in Young Children With Acute Lymphoblastic Leukemia Treated With Cranial Radiation or High-Dose or Very High-Dose Intravenous MethotrexateJournal of Clinical Oncology, 2006
- Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemiaThe Lancet, 2001
- The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 studyBritish Journal of Haematology, 2000
- Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remissionCancer, 2000
- Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experienceBritish Journal of Haematology, 1998
- Survival and endocrine outome after testicular relapse in acute lymphoblastic leukaemiaArchives of Disease in Childhood, 1997
- Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A Childrens Cancer Group studyMedical and Pediatric Oncology, 1996
- Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic LeukemiaNew England Journal of Medicine, 1986
- Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion patternEuropean Journal of Cancer (1965), 1972